Novo Nordisk A/S (NYSE:NVO) Shares Cross Above 50-Day Moving Average – Here’s Why

Shares of Novo Nordisk A/S (NYSE:NVO) passed above its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $40.84 and traded as high as $43.24. Novo Nordisk A/S shares last traded at $42.2070, with a volume of 25,980,432 shares.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo beat analysts’ third-quarter sales and earnings estimates, with obesity-drug sales up 22%. It raised its full-year 2026 sales and operating-profit outlook, citing demand for its GLP-1 medicines. Reuters: Novo Nordisk Q3 profit beats forecast; raises 2026 guidance
• Positive Sentiment: Wegovy pill sales exceeded expectations, helping bolster the outlook and Novo’s position in the weight-loss market. The company added 1.3 million patients in Q3 and plans to bring the pill to more than 20 markets by mid-2027. BioPharma Dive: Novo gets much-needed lift as Wegovy pill tops Wall Street forecasts
• Positive Sentiment: Novo and Abbott expanded their collaboration on a diabetes drug in Asia, potentially supporting broader reach in the region. MarketScreener: Abbott and Novo Nordisk expand collaboration on diabetes drug in Asia
• Neutral Sentiment: CEO Mike Doustdar declined to provide 2027 guidance. He cited factors that could support or weigh on next year’s sales, leaving investors without a firm view of growth beyond 2026. The Motley Fool: Novo Nordisk Stock Jumped After Earnings — But Its CEO Won’t Give 2027 Guidance
• Negative Sentiment: Despite the outlook increase, Jefferies did not upgrade its rating, and Deutsche Bank reiterated a sell rating while raising its price target. Pricing pressure and weakness in diabetes products remain risks; impairment charges also weighed on reported operating profit. MarketScreener: Deutsche Bank raises price target, reiterates sell

Wall Street Analyst Weigh In

NVO has been the topic of several recent analyst reports. BMO Capital Markets set a $40.00 price target on Novo Nordisk A/S and gave the company a “market perform” rating in a research note on Monday, October 12th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, September 21st. Barclays reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 7th. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Novo Nordisk A/S in a research report on Tuesday, September 29th. Finally, Cfra lowered shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating and set a $38.00 target price on the stock. in a research note on Tuesday, September 22nd. Five investment analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and five have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $59.44.

Novo Nordisk A/S Price Performance

The firm has a market capitalization of $188.45 billion, a P/E ratio of 10.32, a price-to-earnings-growth ratio of 1.36 and a beta of 0.70. The business has a 50-day moving average of $40.84 and a 200 day moving average of $44.07. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. The business had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%. On average, sell-side analysts predict that Novo Nordisk A/S will post 3.42 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Novo Nordisk A/S

Several hedge funds and other institutional investors have recently modified their holdings of NVO. Arrowstreet Capital Limited Partnership acquired a new stake in Novo Nordisk A/S in the 1st quarter valued at $287,660,000. State Street Corp raised its holdings in Novo Nordisk A/S by 0.6% during the second quarter. State Street Corp now owns 5,869,834 shares of the company’s stock worth $284,565,000 after buying an additional 32,641 shares during the last quarter. Envestnet Asset Management Inc. raised its holdings in Novo Nordisk A/S by 1.8% during the second quarter. Envestnet Asset Management Inc. now owns 4,031,114 shares of the company’s stock worth $193,250,000 after buying an additional 71,684 shares during the last quarter. Royal Bank of Canada lifted its stake in shares of Novo Nordisk A/S by 3.2% in the first quarter. Royal Bank of Canada now owns 4,527,779 shares of the company’s stock valued at $166,396,000 after buying an additional 141,376 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in shares of Novo Nordisk A/S by 6.7% in the first quarter. Renaissance Technologies LLC now owns 3,397,121 shares of the company’s stock valued at $124,844,000 after buying an additional 213,443 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.